The LHRH antagonist Cetrorelix: A review

T. Reissmann, Andrew V Schally, P. Bouchard, H. Riethmüller, J. Engel

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antagonists which cause an immediate and dose-related inhibition of LH and FSH by competitive blockade of the receptors is much more advantageous. One of the most advanced antagonist produced to date is Cetrorelix, a decapeptide which has been shown to be safe and effective in inhibiting LH and sex-steroid secretion in a variety of animal species and in clinical studies as well. Clinical trials in patients suffering from advanced carcinoma of the prostate, benign prostate hyperplasia, and ovarian cancer are currently in progress and have already shown the usefulness of this new treatment modality. In particular, the concept that a complete suppression of sex-steroids may not be necessary in indications such as uterine fibroma, endometriosis and benign prostatic hyperplasia represents a promising novel perspective for treatment of these diseases. Following completion of phase III trials in controlled ovarian stimulation for IVF regimens, Cetrorelix was given marketing approval and, thus, became the first LHRH antagonist available clinically.

Original languageEnglish
Pages (from-to)322-331
Number of pages10
JournalHuman Reproduction Update
Volume6
Issue number4
StatePublished - Sep 11 2000
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Steroids
Ovulation Induction
Prostatic Hyperplasia
Leiomyoma
Endometriosis
Marketing
Gonadotropins
Ovarian Neoplasms
Hyperplasia
Prostate
Prostatic Neoplasms
Clinical Trials
Hormones
Carcinoma
Therapeutics
cetrorelix
Clinical Studies

Keywords

  • Benign prostatic hyperplasia
  • Cancer treatment
  • GnRH antagonist
  • Gonadotrophins
  • Ovarian stimulation

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Reissmann, T., Schally, A. V., Bouchard, P., Riethmüller, H., & Engel, J. (2000). The LHRH antagonist Cetrorelix: A review. Human Reproduction Update, 6(4), 322-331.

The LHRH antagonist Cetrorelix : A review. / Reissmann, T.; Schally, Andrew V; Bouchard, P.; Riethmüller, H.; Engel, J.

In: Human Reproduction Update, Vol. 6, No. 4, 11.09.2000, p. 322-331.

Research output: Contribution to journalArticle

Reissmann, T, Schally, AV, Bouchard, P, Riethmüller, H & Engel, J 2000, 'The LHRH antagonist Cetrorelix: A review', Human Reproduction Update, vol. 6, no. 4, pp. 322-331.
Reissmann T, Schally AV, Bouchard P, Riethmüller H, Engel J. The LHRH antagonist Cetrorelix: A review. Human Reproduction Update. 2000 Sep 11;6(4):322-331.
Reissmann, T. ; Schally, Andrew V ; Bouchard, P. ; Riethmüller, H. ; Engel, J. / The LHRH antagonist Cetrorelix : A review. In: Human Reproduction Update. 2000 ; Vol. 6, No. 4. pp. 322-331.
@article{963b2d51fbc54b4ab83af8cba27cc566,
title = "The LHRH antagonist Cetrorelix: A review",
abstract = "In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antagonists which cause an immediate and dose-related inhibition of LH and FSH by competitive blockade of the receptors is much more advantageous. One of the most advanced antagonist produced to date is Cetrorelix, a decapeptide which has been shown to be safe and effective in inhibiting LH and sex-steroid secretion in a variety of animal species and in clinical studies as well. Clinical trials in patients suffering from advanced carcinoma of the prostate, benign prostate hyperplasia, and ovarian cancer are currently in progress and have already shown the usefulness of this new treatment modality. In particular, the concept that a complete suppression of sex-steroids may not be necessary in indications such as uterine fibroma, endometriosis and benign prostatic hyperplasia represents a promising novel perspective for treatment of these diseases. Following completion of phase III trials in controlled ovarian stimulation for IVF regimens, Cetrorelix was given marketing approval and, thus, became the first LHRH antagonist available clinically.",
keywords = "Benign prostatic hyperplasia, Cancer treatment, GnRH antagonist, Gonadotrophins, Ovarian stimulation",
author = "T. Reissmann and Schally, {Andrew V} and P. Bouchard and H. Riethm{\"u}ller and J. Engel",
year = "2000",
month = "9",
day = "11",
language = "English",
volume = "6",
pages = "322--331",
journal = "Human Reproduction Update",
issn = "1355-4786",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - The LHRH antagonist Cetrorelix

T2 - A review

AU - Reissmann, T.

AU - Schally, Andrew V

AU - Bouchard, P.

AU - Riethmüller, H.

AU - Engel, J.

PY - 2000/9/11

Y1 - 2000/9/11

N2 - In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antagonists which cause an immediate and dose-related inhibition of LH and FSH by competitive blockade of the receptors is much more advantageous. One of the most advanced antagonist produced to date is Cetrorelix, a decapeptide which has been shown to be safe and effective in inhibiting LH and sex-steroid secretion in a variety of animal species and in clinical studies as well. Clinical trials in patients suffering from advanced carcinoma of the prostate, benign prostate hyperplasia, and ovarian cancer are currently in progress and have already shown the usefulness of this new treatment modality. In particular, the concept that a complete suppression of sex-steroids may not be necessary in indications such as uterine fibroma, endometriosis and benign prostatic hyperplasia represents a promising novel perspective for treatment of these diseases. Following completion of phase III trials in controlled ovarian stimulation for IVF regimens, Cetrorelix was given marketing approval and, thus, became the first LHRH antagonist available clinically.

AB - In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antagonists which cause an immediate and dose-related inhibition of LH and FSH by competitive blockade of the receptors is much more advantageous. One of the most advanced antagonist produced to date is Cetrorelix, a decapeptide which has been shown to be safe and effective in inhibiting LH and sex-steroid secretion in a variety of animal species and in clinical studies as well. Clinical trials in patients suffering from advanced carcinoma of the prostate, benign prostate hyperplasia, and ovarian cancer are currently in progress and have already shown the usefulness of this new treatment modality. In particular, the concept that a complete suppression of sex-steroids may not be necessary in indications such as uterine fibroma, endometriosis and benign prostatic hyperplasia represents a promising novel perspective for treatment of these diseases. Following completion of phase III trials in controlled ovarian stimulation for IVF regimens, Cetrorelix was given marketing approval and, thus, became the first LHRH antagonist available clinically.

KW - Benign prostatic hyperplasia

KW - Cancer treatment

KW - GnRH antagonist

KW - Gonadotrophins

KW - Ovarian stimulation

UR - http://www.scopus.com/inward/record.url?scp=0033849284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033849284&partnerID=8YFLogxK

M3 - Article

C2 - 10972520

AN - SCOPUS:0033849284

VL - 6

SP - 322

EP - 331

JO - Human Reproduction Update

JF - Human Reproduction Update

SN - 1355-4786

IS - 4

ER -